skip to main content
Idioma:
Resultados 1 2 3 4 next page
Mostrar Somente
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia
Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia
Material Type:
Artigo 		Adicionar ao Meu Espaço

Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia

Davis, John B ; Gray, Julie ; Gunthorpe, Martin J ; Hatcher, Jonathan P ; Davey, Phil T ; Overend, Philip ; Harries, Mark H ; Latcham, Judi ; Clapham, Colin ; Atkinson, Kirsty ; Hughes, Stephen A ; Rance, Kim ; Grau, Evelyn ; Harper, Alex J ; Pugh, Perdita L ; Rogers, Derek C ; Bingham, Sharon ; Randall, Andrew ; Sheardown, Steven A

Nature (London), 2000-05, Vol.405 (6783), p.183-187 [Periódico revisado por pares]

London: Nature Publishing

Texto completo disponível

Citações Citado por
2
Systemic administration of Abeta mAb reduces retinal deposition of Abeta and activated complement C3 in age-related macular degeneration mouse model
Systemic administration of Abeta mAb reduces retinal deposition of Abeta and activated complement C3 in age-related macular degeneration mouse model
Material Type:
Artigo 		Adicionar ao Meu Espaço

Systemic administration of Abeta mAb reduces retinal deposition of Abeta and activated complement C3 in age-related macular degeneration mouse model

Catchpole, Ian ; Germaschewski, Volker ; Hoh Kam, Jaimie ; Lundh von Leithner, Peter ; Ford, Susannah ; Gough, Gerald ; Adamson, Peter ; Overend, Philip ; Hilpert, Jan ; López, Francisco J ; Ng, Yin Shan Eric ; Coffey, Pete ; Jeffery, Glen Langmann, Thomas

PloS one, 2013-06, Vol.8 (6), p.e65518-e65518 [Periódico revisado por pares]

United States: Public Library of Science

Texto completo disponível

Citações Citado por
3
Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor Non‐Small Cell Lung Cancer
Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor Non‐Small Cell Lung Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor Non‐Small Cell Lung Cancer

Johnson, Martin ; Serra Traynor, Carlos ; Vishwanathan, Karthick ; Overend, Philip ; Hartmaier, Ryan ; Markovets, Aleksandra ; Chmielecki, Juliann ; Mugundu, Ganesh M. ; Barrett, J. Carl ; Tomkinson, Helen ; Ramalingam, Suresh S.

Clinical pharmacology and therapeutics, 2024-02, Vol.115 (2), p.349-360 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
4
Abstract CT024: Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC)
Abstract CT024: Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract CT024: Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC)

Vishwanathan, Karthick ; Dunyak, James ; Overend, Philip ; Hartmaier, Ryan ; Markovets, Aleksandra ; Chmielecki, Juliann ; Mugundu, Ganesh ; Barrett, Carl ; Tomkinson, Helen ; Johnson, Martin

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT024-CT024 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study

Ahn, Myung-Ju ; Kim, Dong-Wan ; Cho, Byoung Chul ; Kim, Sang-We ; Lee, Jong Seok ; Ahn, Jin-Seok ; Kim, Tae Min ; Lin, Chia-Chi ; Kim, Hye Ryun ; John, Thomas ; Kao, Steven ; Goldman, Jonathan W ; Su, Wu-Chou ; Natale, Ronald ; Rabbie, Sarit ; Harrop, Bryony ; Overend, Philip ; Yang, Zhenfan ; Yang, James Chih-Hsin

The lancet respiratory medicine, 2017-11, Vol.5 (11), p.891-902 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Evaluation of the spontaneously hypertensive rat as a model of attention deficit hyperactivity disorder: acquisition and performance of the DRL-60s test
Evaluation of the spontaneously hypertensive rat as a model of attention deficit hyperactivity disorder: acquisition and performance of the DRL-60s test
Material Type:
Artigo 		Adicionar ao Meu Espaço

Evaluation of the spontaneously hypertensive rat as a model of attention deficit hyperactivity disorder: acquisition and performance of the DRL-60s test

Bull, Eleanor ; Reavill, Charlie ; Hagan, Jim J ; Overend, Philip ; Jones, Declan N.C

Behavioural brain research, 2000-04, Vol.109 (1), p.27-35 [Periódico revisado por pares]

Shannon: Elsevier B.V

Texto completo disponível

Citações Citado por
7
Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
Material Type:
Artigo 		Adicionar ao Meu Espaço

Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

KURRASCH, Regina ; BROWN, Judith C ; CHU, Myron ; CRAIGEN, Jenny ; OVEREND, Philip ; PATEL, Bela ; WOLFE, Steven ; CHANG, David J

Journal of rheumatology, 2013-07, Vol.40 (7), p.1089-1096 [Periódico revisado por pares]

Toronto, ON: Journal of Rheumatology Publishing

Texto completo disponível

Citações Citado por
8
A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors
A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors

Johnson, Melissa Lynne ; Cosaert, Jan G. C. E. ; Falchook, Gerald Steven ; Jones, Suzanne Fields ; Strickland, Donald ; Greenlees, Carol ; Charlton, Julie ; MacDonald, Alexander ; Overend, Philip ; Adelman, Carrie ; Burris, Howard A. ; Pease, Elizabeth J. ; Patel, Gargi Surendra ; Wang, Judy Sing-Zan

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3098-3098 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy
A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

Donnellan, William B. ; Atallah, Ehab L. ; Asch, Adam S. ; Patel, Manish R ; Charlton, Julie ; MacDonald, Alexander ; Young, Elena ; Sainsbury, Elizabeth ; Strickland, Donald ; Jones, Suzanne ; Overend, Philip ; Adelman, Carrie A. ; Travers, Jon ; Smith, Simon ; Pease, J. Elizabeth ; Brugger, Wolfram

Blood, 2018-11, Vol.132 (Supplement 1), p.4064-4064 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
10
A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy
A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Donnellan, William B. ; Atallah, Ehab L. ; Asch, Adam S. ; Patel, Manish R. ; Yang, Jay ; Eghtedar, Alireza ; Borthakur, Gautam M. ; Charlton, Julie ; MacDonald, Alexander ; Korzeniowska, Anna ; Sainsbury, Elizabeth ; Strickland, Donald K. ; Jones, Suzanne ; Overend, Philip ; Adelman, Carrie A. ; Fabbri, Giulia ; Travers, Jon ; Smith, Simon ; Pease, J. Elizabeth ; Cosaert, Jan

Blood, 2019-11, Vol.134 (Supplement_1), p.3919-3919 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (31)
  2. Revistas revisadas por pares (28)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (28)
  2. Livros  (2)
  3. Book Chapters  (2)
  4. Conjunto de Dados  (1)
  5. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de2001  (4)
  2. 2001Até2003  (4)
  3. 2004Até2016  (8)
  4. 2017Até2020  (12)
  5. Após 2020  (7)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.